Clot-targeted magnetic hyperthermia permeabilizes blood clots to make them more susceptible to thrombolysis.

ABSTRACT:

Background

Thrombolysis is a frontline treatment for stroke, which involves the application of tissue plasminogen activator (tPA) to trigger endogenous clot-degradation pathways. However, it is only effective within 4.5 h of symptom onset because of clot contraction preventing tPA permeation into the clot. Magnetic hyperthermia (MH) mediated by tumor-targeted magnetic nanoparticles is used to treat cancer by using local heat generation to trigger apoptosis of cancer cells.

Objectives

To develop clot-targeting magnetic nanoparticles to deliver MH to the surface of human blood clots, and to assess whether this can improve the efficacy of thrombolysis of contracted blood clots.

Methods

Clot-targeting magnetic nanoparticles were developed by functionalizing iron oxide nan

SUBMITTER: Cabrera D 

PROVIDER: S-EPMC9826519 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature